The 2030 Roadmap
A realistic timeline of the technologies and trials that could deliver a complete hair loss cure by the end of this decade.
JAK Inhibitors
FDA approves baricitinib and ritlecitinib for alopecia areata, first systemic treatments ever approved for the condition.
Exosome Therapies
Multiple clinics begin offering exosome-based scalp injections. Early trial data shows promise for androgenetic alopecia with an effect size comparable to PRP.
Stem Cell & Cloning Trials
Phase I trials underway for follicle stem cell transplantation. Stemson Therapeutics completes first human safety study for iPSC-derived hair follicles.
CRISPR for DHT Sensitivity
First-in-human CRISPR trials targeting the androgen receptor gene in follicle dermal papilla cells begun in South Korea. Phase 1 safety data anticipated.
Follicle Multiplication
If Phase II data holds, follicle multiplication via in-vitro expansion of dermal papilla cells could enter Phase III trials with regulatory approval in sight.
Combination Biologics
A Wnt pathway activator or exosome product with acceptable safety profile could reach regulatory submission. Combination protocols being optimised.
Personalised Protocols
Gene therapy, biologics, and energy device combinations personalised by genetic profile. Clascoterone and pyrilutamide likely commercially available.
100% Reversal Possible?
For most forms of pattern hair loss, a combination of approved treatments achieving full, durable reversal is a realistic clinical target. Not guaranteed, but credibly within reach.
This roadmap is maintained by our editorial team based on published trial data, regulatory filings, and researcher interviews. It is not a guarantee of any specific outcome.